Key Takeaways
- ImmunityBio received an FDA warning letter concerning a television commercial and podcast episode containing misleading statements about ANKTIVA, its bladder cancer treatment
- Marketing materials falsely implied ANKTIVA could address all cancer types — regulatory approval only covers a narrow bladder cancer indication used with BCG therapy
- Company leadership including CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong were specifically named in the FDA’s enforcement action
- This represents ImmunityBio’s third regulatory notice regarding promotional compliance issues since September 2025
- ImmunityBio must submit a corrective action plan within 15 working days or potentially face legal enforcement measures
Shares of ImmunityBio experienced a significant decline on Tuesday following regulatory scrutiny over marketing materials that overstated the approved applications of its cancer medication ANKTIVA, representing the third time federal regulators have intervened over promotional concerns.
The Food and Drug Administration’s Office of Prescription Drug Promotion dispatched a formal warning letter to ImmunityBio regarding a television advertisement and podcast episode titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” Regulators concluded both pieces violated federal pharmaceutical marketing statutes.
The fundamental problem centered on overreach. ANKTIVA has regulatory clearance for a highly specific application: treating adults with BCG-unresponsive non-muscle invasive bladder cancer featuring carcinoma in situ, with or without papillary tumors, delivered via intravesical administration in combination with BCG therapy.
The advertising content dramatically exceeded this narrow authorization. Claims presented in the materials indicated ANKTIVA could “treat all cancers,” serve as a prophylactic measure for radiation exposure victims, and function effectively as a single-dose injectable treatment. Federal regulators emphasized that none of these assertions have clinical validation or regulatory approval.
Both company executives — CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong — participated in the promotional content and were explicitly identified in the FDA’s enforcement correspondence.
According to the agency, these materials resulted in misbranding ANKTIVA and rendered the medication’s commercial distribution a breach of the Federal Food, Drug, and Cosmetic Act.
Pattern of Regulatory Concerns
Tuesday’s enforcement action is far from ImmunityBio‘s initial encounter with regulators over advertising standards. The FDA previously dispatched untitled letters in both September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional deficiencies.
The current correspondence represents the third regulatory communication — and carries substantially greater consequences. Warning letters from the FDA possess significantly more enforcement authority than untitled letters and demonstrate the agency’s intensifying concerns about compliance.
Regulators also criticized ImmunityBio for inadequate presentation of safety information within the marketing materials and for excluding critical details about the medication’s precise approved indication.
Additionally, the podcast episode was not submitted to FDA review at the time of its original distribution, representing a separate regulatory compliance failure.
Investor Response
IBRX shares declined approximately 15% to 21% during Tuesday’s trading session, with several market observers documenting intraday losses reaching 21% during morning hours.
ImmunityBio has been granted 15 working days to provide the FDA with a comprehensive written response detailing corrective measures to address the cited violations.
The biotechnology firm must also develop and distribute corrective communications specifically targeting individuals who were exposed to the misleading promotional content.
Federal regulators cautioned that inadequate remedial action could trigger formal legal proceedings.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
